A randomized, double-blind phase II/III study (NCT05785767) is investigating fianlimab (αLAG-3) combined with cemiplimab (αPD-1) as first- line therapy for advanced NSCLC with PD-L1≥50%, including patients previously treated with PD-1/L1 or CTLA-4 inhibitors. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.